Systematic review of the relationship between bladder and bowel function: Implications for patient management

International Journal of Clinical Practice

Volumn 67, Issue 3, 2013, Pages 205-216

  Kaplan, S A ^a   Dmochowski, R ^b   Cash, B D ^c   Kopp, Z S ^d   Berriman, S J ^d   Khullar, V ^e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c Walter Reed National Military   (United States)

^d PFIZER INC   (United States)

^e ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT;

BLADDER FUNCTION; CLINICAL PRACTICE; CONSTIPATION; CROSS ALLERGY; CYSTITIS; HUMAN; INTESTINAL DYSMOTILITY; INTESTINE DISTENSION; INTESTINE FUNCTION; IRRITABLE COLON; LOWER URINARY TRACT SYMPTOM; LUMBOSACRAL SPINE; NONHUMAN; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SPINAL CORD NERVE CELL; SYSTEMATIC REVIEW; URINE INCONTINENCE;

ADULT; ANIMALS; CHRONIC PAIN; CONSTIPATION; FECAL INCONTINENCE; FEMALE; HUMANS; MALE; PELVIC ORGAN PROLAPSE; PELVIC PAIN; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; YOUNG ADULT;

EID: 84874040073     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12028     Document Type: Review

References (75)

1. Malykhina AP,. Neural mechanisms of pelvic organ cross-sensitization. Neuroscience 2007; 149: 660-72.
2. Christianson JA, Liang R, Ustinova EE, et al., Convergence of bladder and colon sensory innervation occurs at the primary afferent level. Pain 2007; 128: 235-43.
3. Malykhina AP, Qin C, Greenwood-van Meerveld B, et al., Hyperexcitability of convergent colon and bladder dorsal root ganglion neurons after colonic inflammation: mechanism for pelvic organ cross-talk. Neurogastroenterol Motil 2006; 18: 936-48.
4. Keast JR, De Groat WC,. Segmental distribution and peptide content of primary afferent neurons innervating the urogenital organs and colon of male rats. J Comp Neurol 1992; 319: 615-23.
5. Ustinova EE, Fraser MO, Pezzone MA,. Cross-talk and sensitization of bladder afferent nerves. Neurourol Urodyn 2010; 29: 77-81.
6. Whorwell PJ, Lupton EW, Erduran D, Wilson K,. Bladder smooth muscle dysfunction in patients with irritable bowel syndrome. Gut 1986; 27: 1014-7.
7. Loening-Baucke V,. Urinary incontinence and urinary tract infection and their resolution with treatment of chronic constipation of childhood. Pediatrics 1997; 100: 228-32.
8. Abrams P, Kelleher C, Lerr L, Rogers R,. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6: S580-90.
9. Damon H, Dumas P, Mion F,. Impact of anal incontinence and chronic constipation on quality of life. Gastroenterol Clin Biol 2004; 28: 16-20.
10. Dennison C, Prasad M, Lloyd A, et al., The health-related quality of life and economic burden of constipation. Pharmacoeconomics 2005; 23: 461-76.
11. Franco I,. Overactive bladder in children. Part 1: pathophysiology. J Urol 2007; 178: 761-8; discussion 8.
12. Ouslander JG,. Management of overactive bladder. N Engl J Med 2004; 350: 786-99.
13. Yamanishi T, Chapple CR, Chess-Williams R,. Which muscarinic receptor is important in the bladder? World J Urol 2001; 19: 299-306.
14. Birder L, Drake M,. Neural control. In:, Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence, 4th edn. Paris: Health Publications Ltd, 2009: 167-253.
15. McCloskey KD,. Interstitial cells in the urinary bladder-localization and function. Neurourol Urodyn 2010; 29: 82-7.
16. McCloskey KD, Gurney AM,. Kit positive cells in the guinea pig bladder. J Urol 2002; 168: 832-6.
17. Davidson RA, McCloskey KD,. Morphology and localization of interstitial cells in the guinea pig bladder: structural relationships with smooth muscle and neurons. J Urol 2005; 173: 1385-90.
18. McCloskey KD,. Calcium currents in interstitial cells from the guinea-pig bladder. BJU Int 2006; 97: 1338-43.
19. Johnston L, Carson C, Lyons AD, et al., Cholinergic-induced Ca2+ signaling in interstitial cells of Cajal from the guinea pig bladder. Am J Physiol Renal Physiol 2008; 294: F645-55.
20. Brading AF, McCloskey KD,. Mechanisms of disease: specialized interstitial cells of the urinary tract-an assessment of current knowledge. Nat Clin Pract Urol 2005; 2: 546-54.
21. De Wachter S, Wyndaele JJ,. Impact of rectal distention on the results of evaluations of lower urinary tract sensation. J Urol 2003; 169: 1392-4.
22. Pezzone MA, Liang R, Fraser MO,. A model of neural cross-talk and irritation in the pelvis: implications for the overlap of chronic pelvic pain disorders. Gastroenterology 2005; 128: 1953-64.
23. De Wachter S, de Jong A, Van Dyck J, Wyndaele JJ,. Interaction of filling related sensation between anorectum and lower urinary tract and its impact on the sequence of their evacuation. A study in healthy volunteers. Neurourol Urodyn 2007; 26: 481-5.
24. Qin C, Foreman RD,. Viscerovisceral convergence of urinary bladder and colorectal inputs to lumbosacral spinal neurons in rats. Neuroreport 2004; 15: 467-71.
25. Qin C, Malykhina AP, Akbarali HI, Foreman RD,. Cross-organ sensitization of lumbosacral spinal neurons receiving urinary bladder input in rats with inflamed colon. Gastroenterology 2005; 129: 1967-78.
26. Chen SS, Yang CC, Chien CT,. Colorectal distension enforce acute urinary bladder distension-induced hepatic vasoconstriction in the rat. Neurosci Lett 2008; 443: 257-60.
27. Noronha R, Akbarali H, Malykhina A, et al., Changes in urinary bladder smooth muscle function in response to colonic inflammation. Am J Physiol Renal Physiol 2007; 293: F1461-7.
28. Rudick CN, Chen MC, Mongiu AK, Klumpp DJ,. Organ cross talk modulates pelvic pain. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1191-8.
29. Panayi DC, Khullar V, Digesu GA, et al., Rectal distension: the effect on bladder function. Neurourol Urodyn 2011; 30: 344-7.
30. Francis CY, Duffy JN, Whorwell PJ, Morris J,. High prevalence of irritable bowel syndrome in patients attending urological outpatient departments. Dig Dis Sci 1997; 42: 404-7.
31. Monga AK, Marrero JM, Stanton SL, et al., Is there an irritable bladder in the irritable bowel syndrome? Br J Obstet Gynaecol 1997; 104: 1409-12.
32. Alagiri M, Chottiner S, Ratner V, et al., Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. Urology 1997; 49: 52-7.
33. Khullar V, Damiano R, Toozs-Hobson P, Cardozo L,. Prevalence of faecal incontinence among women with urinary incontinence. Br J Obstet Gynaecol 1998; 105: 1211-3.
34. Soligo M, Salvatore S, Milani R, et al., Double incontinence in urogynecologic practice: a new insight. Am J Obstet Gynecol 2003; 189: 438-43.
35. Manning J, Eyers AA, Korda A, et al., Is there an association between fecal incontinence and lower urinary dysfunction? Dis Colon Rectum 2001; 44: 790-8.
36. Coyne KS, Cash B, Kopp Z, et al., The prevalence of chronic constipation and faecal incontinence among men and women with symptoms of overactive bladder. BJU Int 2011; 107: 254-61.
37. Manning J, Korda A, Benness C, Solomon M,. The association of obstructive defecation, lower urinary tract dysfunction and the benign joint hypermobility syndrome: a case-control study. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14: 128-32.
38. Spence-Jones C, Kamm MA, Henry MM, Hudson CN,. Bowel dysfunction: a pathogenic factor in uterovaginal prolapse and urinary stress incontinence. Br J Obstet Gynaecol 1994; 101: 147-52.
39. Ng SC, Chen YC, Lin LY, Chen GD,. Anorectal dysfunction in women with urinary incontinence or lower urinary tract symptoms. Int J Gynaecol Obstet 2002; 77: 139-45.
40. Longstreth GF, Thompson WG, Chey WD, et al., Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
41. Ginsberg DA, Phillips SE, Wallace J, Josephson KL,. Evaluating and managing constipation in the elderly. Urol Nurs 2007; 27: 191-200. quiz 1.
42. Cash BD, Chang L, Sabesin SM, Vitat P,. Update on the management of adults with chronic idiopathic constipation. J Fam Pract 2007; 56: S13-9.quiz S20.
43. Garrigues V, Galvez C, Ortiz V, et al., Prevalence of constipation: agreement among several criteria and evaluation of the diagnostic accuracy of qualifying symptoms and self-reported definition in a population-based survey in Spain. Am J Epidemiol 2004; 159: 520-6.
44. Higgins PD, Johanson JF,. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004; 99: 750-9.
45. Abrams P, Cardozo L, Fall M, et al., The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.
46. Haylen BT, de Ridder D, Freeman RM, et al., An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29: 4-20.
47. Irwin DE, Milsom I, Hunskaar S, et al., Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-15.
48. Milsom I, Abrams P, Cardozo L, et al., How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6.
49. Stewart WF, Van Rooyen JB, Cundiff GW, et al., Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36.
50. Kannan H, Radican L, Turpin RS, Bolge SC,. Burden of illness associated with lower urinary tract symptoms including overactive bladder/urinary incontinence. Urology 2009; 74: 34-8.
51. Irvine EJ, Ferrazzi S, Pare P, et al., Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 2002; 97: 1986-93.
52. Glia A, Lindberg G,. Quality of life in patients with different types of functional constipation. Scand J Gastroenterol 1997; 32: 1083-9.
53. Grotz RL, Pemberton JH, Talley NJ, et al., Discriminant value of psychological distress, symptom profiles, and segmental colonic dysfunction in outpatients with severe idiopathic constipation. Gut 1994; 35: 798-802.
54. Martin BC, Barghout V, Cerulli A,. Direct medical costs of constipation in the United States. Manag Care Interface 2006; 19: 43-9.
55. Irwin DE, Mungapen L, Milsom I, et al., The economic impact of overactive bladder syndrome in six Western countries. BJU Int 2009; 103: 202-9.
56. Onukwugha E, Zuckerman IH, McNally D, et al., The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care 2009; 15: S90-7.
57. Singh G, Lingala V, Wang H, et al., Use of health care resources and cost of care for adults with constipation. Clin Gastroenterol Hepatol 2007; 5: 1053-8.
58. Darkow T, Fontes CL, Williamson TE,. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy 2005; 25: 511-9.
59. Talley NJ, Lasch KL, Baum CL,. A gap in our understanding: chronic constipation and its comorbid conditions. Clin Gastroenterol Hepatol 2009; 7: 9-19.
60. Cardozo L, Robinson D,. Special considerations in premenopausal and postmenopausal women with symptoms of overactive bladder. Urology 2002; 60: 64-71.discussion
61. Zhang W, Song Y, He X, et al., Prevalence and risk factors of overactive bladder syndrome in Fuzhou Chinese women. Neurourol Urodyn 2006; 25: 717-21.
62. Alling Moller L, Lose G, Jorgensen T,. Risk factors for lower urinary tract symptoms in women 40 to 60 years of age. Obstet Gynecol 2000; 96: 446-51.
63. Charach G, Greenstein A, Rabinovich P, et al., Alleviating constipation in the elderly improves lower urinary tract symptoms. Gerontology 2001; 47: 72-6.
64. Locke GR, 3rd, Pemberton JH, Phillips SF,. AGA technical review on constipation. American Gastroenterological Association. Gastroenterology 2000; 119: 1766-78.
65. Chapple CR, Khullar V, Gabriel Z, et al., The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543-62.
66. Toviaz® (fesoterodine fumarate). Full Prescribing Information. New York: Pfizer Inc 2008.
67. VESIcare® (solifenacin succinate). Full Prescribing Information. North Carolina: Astellas Pharma, Norman, Oklahoma, and GlaxoSmithKline, Research Triangle Park, 2008.
68. Ditropan® XL (oxybutynin chloride). Full Prescribing Information. Vacaville, California: ALZA Corporation, 2009.
69. Newman DK, Ee CH, Gordon D, et al., Continence promotion, education & primary prevention. In:, Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence, 4th edn. Paris: Health Publications Ltd 21, 2009: 1643-84.
70. Sanctura® XR (trospium chloride). Full Prescribing Information. Irvine, California: Allergan, Inc., 2007.
71. Enablex® (darifenacin hydrobromide). Full Prescribing Information. Stein, Switzerland: Novartis Pharma Stein AG, 2008.
72. Chapple C, Steers W, Norton P, et al., A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005; 95: 993-1001.
73. Bharucha AE, Seide B, Guan Z, et al., Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects. Neurogastroenterol Motil 2008; 20: 643-8.
74. Locke GR, 3rd, Pemberton JH, Phillips SF,. American Gastroenterological Association Medical Position Statement: guidelines on constipation. Gastroenterology 2000; 119: 1761-6.
75. Staskin DR, MacDiarmid SA,. Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. Am J Med 2006; 119: 9-15.